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Current Issues
here’s been a voracious uptake of drug-eluting stents worldwide since their
introduction in 2002. In January 2005, Boston Scientific Corporation an-
nounced that 1 million TAXUS stents had been implanted.1 This was fol-
lowed in February 2005 by Cordis Corporation’s announcement that 1 million
patients had received approximately 1.5 million CYPHER stents.2 So there are now
over 2.5 million stents implanted; at about $2,000 each, that equals $5 billion. At
the Thoraxcenter, it’s been no different: very early in April 2002, we made the de-
cision that this was to be our preferred therapy. We are now approaching 3 years of
use, and over 8,000 drug-eluting stents have been implanted in nearly 4,000 pa-
tients at our institution.
Early Stent Thrombosis
There is a potential downside to these stents, namely stent thrombosis. There are 2
distinct types: early stent thrombosis, which occurs within the first 30 days, and
late stent thrombosis, which occurs after 30 days. For bare-metal stents, the inci-
dence of early stent thrombosis is low. Cutlip and coworkers3 pooled 6 trials with a
total of 6,000 patients and documented an incidence of 0.9%. Orford4 looked at
4,500 patients in the Mayo Clinic registry and reported an incidence of 0.51%.
The problem is that patients with stent thrombosis have a 70% to 87% risk of
death or nonfatal MI.
We recently published a series of 2,512 patients who underwent stenting: 506
with bare-metal stents, 1,017 with sirolimus-eluting stents, and 989 with pacli-
taxel-eluting stents (Table I).5 Long-term clopidogrel use was different in the 3
groups, but our focus was on the first 30 days, and all 3 had the same dual anti-
platelet therapy during that period. The population was pretty typical for a tertiary
cath lab. Multivessel disease was present in over half of our patients; unstable angi-
na was the indication in a third, and acute MI in a quarter. In the drug-eluting era,
we treated a mean of 1.4 vessels and implanted 2.2 or 2.3 stents per patient, for a
total length of 42 to 44 mm. With drug-eluting stents, we became more aggressive
and implanted more stents and longer stent lengths. Bifurcations were treated in
18% of patients. The incidence of angiographic stent thrombosis in the 3 groups
was basically the same, 1%. However, three quarters of these patients with stent
thrombosis presented with an acute MI, and of those, 3 died, giving us a mortality
rate of 12% (3 patients out of 26 with stent thrombosis) at 30 days. When a broad-
er clinical definition of “possible” stent thrombosis was applied—including pa-
tients with sudden death or out-of-hospital cardiac arrest or myocardial infarction
not attributable to another lesion—the 30-day overall incidence was about 1.5%,
similar for all 3 groups. Importantly, stent thrombosis, if it occurred, tended to do
so in the first 11 days, which suggests that, acutely, a mechanical cause is to blame.
Late Stent Thrombosis
Late stent thrombosis may occur if there’s impaired re-endothelialization of the ves-
sel and the implanted stent, as was seen with coronary brachytherapy in the early
days of its use. The delayed effects of drug-eluting stents in human beings are at
present unknown. Virmani6 and colleagues reported on a patient enrolled in the E-
SIRIUS trial who received 2 sirolimus-eluting stents: at 8-month angiography and
IVUS, he demonstrated vascular enlargement, and at 18 months post-implanta-
tion, he died as a consequence of late stent thrombosis. On autopsy, aneurysm for-
mation and a localized hypersensitivity reaction were found. The authors suspected
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TABLE I. Patient Characteristics in Early Stent Thrombosis Study
BMS SES PES
(n=506) (n=1017) (n=989) P Value
Age (years ± SD) 61 ± 11 61 ± 11 61 ± 11 0.3
Male (%) 73 70 74 0.1
Diabetes mellitus (%) 16 18 17 0.6
Current smoker (%) 35 28 28 <0.01
Hypertension (%) 40 41 41 0.9
Previous MI (%) 43 32 35 <0.01
Previous PCI (%) 22 25 26 0.2
Previous CABG (%) 11 9 8 0.2
Multivessel disease (%) 54 57 56 0.4
Indication <0.01
Unstable angina (%) 35 36 30
AMI (%) 20 19 26
GP IIb/IIIa use (%) 37 21 28 <0.01
Vessels treated (n ± SD) 1.4 ± 0.6 1.4 ± 0.6 1.4 ± 0.6 0.8
Stents implanted (mm ± SD) 1.9 ± 1.1 2.3 ± 1.5 2.2 ± 1.4 <0.01
Total stent length (mm ± SD) 32 ± 22 42 ± 30 44 ± 29 <0.01
Use of ≤2.50-mm stent (%) 23 38 38 <0.01
Bifurcations stented (%) 5 18 17 <0.01
Minimum clopidogrel 1 3 6 <0.01
prescription, months
Incidence of angiographic 6 (1.2) 10 (1.0) 10 (1.0) NS
stent thrombosis (n, %)
Possible stent thrombosis 1 (0.2) 5 (0.5) 6 (0.6) NS
(n, %)
All stent thrombosis (n, %) 7 (1.4) 15 (1.5%) 16 (1.6) NS
AMI = acute myocardial infarction; BMS = bare-metal stent; CABG = coronary artery bypass grafting; GP = glycoprotein; MI =
myocardial infarction; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent; SES =sirolimus-eluting stent
that a reaction to the polymer might have been the
cause.
In a research letter in the Lancet last year,7 we re-
ported 4 cases of late stent thrombosis: 2 patients were
from our center, and 2 were from the Washington
Hospital Center (Table II). All 4 patients were on dual
antiplatelet therapy, aspirin, and clopidogrel for 3 to 
6 months, followed by aspirin therapy. In all 4 pa-
tients, stent thrombosis occurred very late, at least 11
months after stent implantation. It occurred at a time
remote from the mandatory 6-month term of anti-
platelet therapy that is recommended for aspirin and
clopidogrel. These incidents were, however, related to
the cessation of aspirin: these patients were on no an-
tiplatelet therapy at the time of the events. In 3 of the
4 patients, the aspirin was stopped for elective surgery;
the remaining patient stopped it on his own. All 4 pa-
tients received a single large drug-eluting stent, 3 or
3.5 mm in diameter. All presented with an acute myo-
cardial infarction 4 to 14 days after stopping aspirin.
These late thromboses occurred more than 11 months
after stent implantation, at a time when re-endothe-
lialization or healing following drug-eluting stent im-
plantation should have been complete. Patients 3 and
4 are very interesting because each had a bare-metal
stent implanted in another vessel at around the same
time as the drug-eluting stent, and the bare-metal stent
was patent at the time of the stent thrombosis.
We took this a bit further and looked at our over-
all incidence of late angiographic stent thrombosis
(LAST) with drug-eluting stents.8 We took the identi-
cal population that we used when we looked at early
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stent thrombosis: 2,006 patients with drug-eluting
stents. We followed each of these patients for at least a
year, with a mean follow-up of 1.5 years. There were
3 sirolimus-eluting stent thromboses and 5 paclitaxel-
eluting stent thromboses, all of which were angio-
graphically documented, yielding an overall incidence
of 0.35%, with an upper limit to the confidence inter-
val of 0.72%. Of the 8 patients, 2 died, for a mortality
rate of 25%. Importantly, no cases of stent thrombosis
were seen in patients on dual antiplatelet therapy. In 
3 of the 8 patients, both aspirin and clopidogrel had
been stopped. Five patients were on aspirin. In 2 of
these, stent thrombosis occurred within a month of
stopping clopidogrel. Three patients were clinically
very stable on aspirin monotherapy. In 2 patients,
thrombosis occurred very late, 25 and 26 months after
stent implantation. Unfortunately, both patients pre-
sented in cardiogenic shock and died.
To summarize our perspectives of LAST, late stent
thrombosis occurs both in patients who are taking as-
pirin and in those who are not, and cessation of anti-
platelet therapy by cardiologists or other practitioners
requires careful consideration. The risks of stopping
antiplatelet therapy have to be weighed against the
benefits of stopping it, for instance, for surgical pro-
cedures. The incidence of LAST is about 0.35% an-
giographically, but it’s probably clinically higher,
because some cases present as sudden cardiac death or
MI and might never be documented. The cause is 
unknown and needs to be elucidated. Impaired re-
endothelialization, due to the toxic nature of the
agent(s), is a plausible and logical explanation; other
mechanisms, such as hypersensitivity and expansive
remodeling, need to be explored.6 The treatment, un-
fortunately, is unclear. For the secondary prevention
of LAST, in patients who’ve already had one episode,
it seems intuitive to prescribe dual antiplatelet therapy
for an indefinite period of time, and that’s our current
practice. However, for the primary prevention of
LAST, remember that long-term dual antiplatelet ther-
apy is associated with an increased risk of major bleed-
ing, up to 2% in the 1st year.
Neointima Formation
Continued neointima formation over time is a phe-
nomenon observed with drug-eluting stents. We
know that drug-eluting stents are effective because
they reduce neointima or scar formation. However, in
contrast with bare-metal stents, in which neointima
formation peaks at about 6 months and then regress-
es, with drug-eluting stents the neointima may con-
tinue to grow; the true duration of this process has not
been well described. ENDEAVOR I was a study done
in Australia and New Zealand with ABT-578, an ana-
log of sirolimus. Both IVUS and angiography have
documented continued neointima formation during
the 4–12 month period.9 In TAXUS II10 at 6 months,
the neointimal area with drug-eluting stents encom-
passed about 10 to 15 mm2, which was much lower
than with bare stents (about 30 mm2). However, at 2
years, neointimal volume continues to increase with
drug-eluting stents, while with bare stents it regresses.
The FIM study was the pilot study of sirolimus. Serial
IVUS studies were done at 4, 12, 24, and 48 months.
Between zero and 2 years, there was significant neoin-
timal growth; but between 2 and 4 years, it appeared
TABLE II. Patient Characteristics of Late Angiographic Stent Thrombosis (LAST)
Patient 1 2 3 4
Index presentation UAP VF arrest VF arrest SAP
Age (years) 63 73 43 62
Vessel RCA LAD LCx LAD
Stent PES PES SES* SES*
Size (mm) 3.0 × 16 3.5 × 16 3.0 × 33 3.0 × 18
Reason Elective bladder Elective Patient Elective 
polyp resection hemicolectomy decision colonoscopy
for cancer & polypectomy
Symptoms of LAST AMI AMI AMI AMI
Stopped aspirin (days) 5 7 14 4
Months after stent 11.5 14.5 12 11
implantation
*Also had bare-metal stent implanted in another vessel that was patent at repeat angiography
AMI = acute myocardial infarction; LAD = left anterior descending coronary artery; LCx = left circumflex artery; PES = paclitaxel-
eluting stent; RCA = right coronary artery; SAP = stable angina pectoris; SES = sirolimus-eluting stent; UAP = unstable angina
pectoris; VF = ventricular fibrillation
dence of major adverse cardiac events (hazard ratio,
1.33, Table IV). When you adjust for their increased
complexity, the hazard ratio is 1.16—slightly, but not
significantly higher (P = 0.4). ISAR-DESIRE, a study
published in JAMA earlier this year, compared sir-
olimus- and paclitaxel-eluting stents against bal-
loon angioplasty for people with restenosis after
bare-metal stent placement and showed that sir-
olimus-eluting stents had less late loss and less re-
vascularization, but a similar amount of restenosis
compared with paclitaxel-eluting stents.14 Two addi-
tional comparative studies, SIRTAX and REALITY,
were also presented at the 2005 ACC meeting.
Future Devices
The -limus family—sirolimus, rapamycin—has been
shown to be very effective in reducing restenosis. A
number of analogs are also being investigated: evero-
limus by Guidant,15 tacrolimus by Sorin, biolimus-
A9 by BioSensors16 and Terumo, and ABT-578 by
Medtronic9 and Abbott (Fig. 1). Pimecrolimus is yet
to plateau, suggesting that neointimal formation does
stop with drug-eluting stents, but takes a lot longer
compared with bare-metal stents.11
Drug-Eluting Stents versus Surgery
Some very important questions are going to be con-
fronted in the ARTS II, FREEDOM, and SYNTAX
studies. The preliminary 6-month results of ARTS II
were presented last year at the Transcatheter Cardio-
vascular Therapeutics symposium. This was a study
of 607 patients with multivessel disease that com-
pared patients receiving sirolimus-eluting stents with
a historical control group of CABG-treated patients
from ARTS I. In comparison with patients in ARTS
I, those in ARTS II were older and had more diabetes
and more triple-vessel disease; and more stents and
longer stents were implanted. Despite being a more
complex population, at 6 months, the ARTS II stent
group had outcomes that were at least as good, if not
better than, the outcomes in the surgical patients in
ARTS I (but bear in mind that this is a historical com-
parison, and not a randomized trial). The 12-month
results were presented at the ACC meeting and dem-
onstrate that the use of sirolimus-eluting stents for
multivessel disease resulted in a 1-year major adverse
cardiac and cerebral event rate of 10.5%.12 FREEDOM
is an NIH-sponsored randomized trial looking at dia-
betic patients with multivessel disease, and comparing
drug-eluting stents with surgery. The SYNTAX ran-
domized trial will compare TAXUS stents with surgery
in patients with triple-vessel disease and left main dis-
ease.
Stent versus Stent Comparisons
Which drug-eluting stent is better, the sirolimus- or
paclitaxel-eluting stent? Before we can really talk about
“better,” we need to understand what better means.
Different companies push different endpoints (Table
III). Some will say that one endpoint is more impor-
tant; others will say the opposite. It’s up to you as
clinicians to decide for yourselves. There are focused
anatomic endpoints, such as ultrasound measure-
ments of the percentage of volume obstruction or an-
giographic measurements of stenosis severity. There
are also clinical criteria, and these come in many defi-
nitions. Again, you have to decide what you feel mat-
ters most for you or your patients.
I’ve already talked a little bit about our own T-
SEARCH registry,13 a nonrandomized, real-world, un-
selected, all-comers experience. This is a pretty com-
plex group: unstable angina in about a third, acute MI
in about a quarter, cardiogenic shock in 13%, and left
main stenting in 3% to 4% of patients. The paclitaxel
group was more complicated, receiving more stents
and longer stents than did the sirolimus group. And,
not surprisingly, this group had a slightly higher inci-
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TABLE III. End-Point Determinants Used in Various
Clinical Trials
Angiographic Parameters
Minimal lumen diameter at follow-up
Late loss
Binary restenosis
Intravascular Ultrasound Parameters
Mean luminal area
Percentage volume obstruction
Clinical Parameters
“Clinically-driven” target lesion revascularization
Target lesion revascularization
Target vessel revascularization
Target vessel failure
Major adverse cardiac events
TABLE IV. Adjusted Hazard Ratios by Stent Type of
Major Adverse Cardiac Events (MACE), a Composite of
Death, Nonfatal Myocardial Infarction, or Target Vessel
Revascularization at 1-Year Follow-Up from the
T-SEARCH Registry
MACE HR (95% CI) P Value
Unadjusted 1.33 (0.95–1.88) 0.10
Adjusted for significant 1.20 (0.85–1.70) 0.3
predictors of MACE
Adjusted for significant 1.16 (0.81–1.64) 0.4 
univariate variables
A hazard ratio of <1 implies that paclitaxel-eluting stents are
better, >1 implies that sirolimus-eluting stents are better, and
=1 implies no difference. Confidence intervals that cross unity
(1) result in nonsignificant P values.
another one in the early stages. Paclitaxel, used in Bos-
ton Scientific’s TAXUS stent, is now being used by 2
competitors working on new delivery systems. Conor
Medsystems embeds paclitaxel in a biodegradable
polymer inside novel laser-cut wells within the stent
itself, and an Indian company called Sahajanand uses
a 3-layer durable polymer. Totally different is a pro-
healing approach by Orbus Medical, which uses CD-
34 antibodies to capture circulating endothelial
progenitor cells, theoretically to hasten re-endothelial-
ization.17 And, finally, while not strictly a drug-eluting
stent, biodegradable stents such as the one being in-
vestigated by Biotronik hold promise.
Summary
Early stent thrombosis occurs in about 1% to 1.5% of
patients with drug-eluting stents, very similar to the
rate with bare-metal stents. Late stent thrombosis is
more of a concern with drug-eluting stents, with an
incidence of at least 0.35%. I would urge caution if
you feel you have to stop antiplatelet therapy in pa-
tients with drug-eluting stents. While neointima for-
mation peaks at 6 months and then may actually
regress with bare-metal stents, it continues to grow
with drug-eluting stents—although this process ap-
pears to plateau by 4 years with sirolimus. With the
others, we have to wait and see. We still don’t know the
best drug-eluting stent. Trials are under way to com-
pare stents with surgery, and the future brings the 
arrival of a number of exciting new devices and ap-
proaches that are now entering clinical trials.
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